Multiple Sclerosis

Efficacy and safety of a hip flexion assist orthosis in ambulatory multiple sclerosis patients
OBJECTIVE: To evaluate the efficacy and safety of a hip flexion assist orthosis (HFAO) in ambulatory patients with multiple sclerosis (MS).

Cleveland, OH 44195
USA
Living with parental multiple sclerosis: children's experiences and clinical implications
BACKGROUND: Health professionals need to understand how chronic illness affects all family members.

Queensland, Australia
Australia
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Disease-modifying agents (DMAs), including interferon beta (IFNbeta) and glatiramer acetate (GA), are the mainstays of long-term treatment of multiple sclerosis (MS).
100 High Street
Buffalo, NY 14203
USA
Self-generation to improve learning and memory of functional activities in persons with multiple scl
OBJECTIVE: To examine the utility of using a self-generation strategy to improve learning and performance of everyday functional tasks in persons with multiple sclerosis (MS).

West Orange, NJ 07052
USA
Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple scler
BACKGROUND/OBJECTIVE: The objective was to evaluate the effectiveness of neurotoxin treatments of urinary incontinence (UI) in individuals with spinal cord injury (SCI) or multiple sclerosis (MS).

Minneapolis, MN 55417
USA
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple
BACKGROUND: A 24-week phase II trial has shown that 0.3 mg of laquinimod given daily to patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions.

Milan, Italy
Italy
Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction
Balance problems and falls are common in people with multiple sclerosis (MS) but their cause and nature are not well understood.

Portland, OR 97239-3098
USA
[Biological treatment of multiple sclerosis]
In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS).

Copenhagen, Denmark
Denmark
Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-c
BACKGROUND: Suppressing the antigen-presenting capacity of glial cells could represent a novel way of reducing inflammatory activity in multiple sclerosis (MS).

Groningen, The Netherlands
The Netherlands
Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comp
The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the currently available disease-modifying therapies (DMTs).

Ottawa, Canada
Canada